FDA Opens Public Docket on Generative AI-Enabled Medical Devices
The U.S. Food and Drug Administration on Aug. 18 issued a discussion paper seeking public feedback to inform a regulatory approach for generative artificial intelligence–enabled medical devices. The agency requested stakeholder input on topics that include risk assessment, premarket evaluation, postmarket monitoring, foundation models and agentic systems. The FDA opened docket FDA-2026-N-7874 to accept public submissions and set a deadline for comments.
Purpose and framing of the discussion paper
The FDA described the document as a discussion paper intended to gather public and stakeholder perspectives rather than as a final regulation. The agency stated the paper is not a final regulation and that it offers no clinical advice. The stated purpose of the notice is to solicit feedback to inform how the FDA might approach devices that incorporate generative AI capabilities.
Topics the agency seeks input on
The discussion paper requests input on multiple technical and policy areas. The agency identified approaches to assessing risk, methods for premarket evaluation of devices that use generative AI, and considerations for postmarket monitoring. The notice also invites views on how to account for technologies described in the paper as foundation models and agentic systems. These subject areas are set out in the agency’s document as specific topics for stakeholder comment rather than as determinations of policy at this time.
Proposed analytic structure presented for comment
As part of the discussion paper, the FDA presented a potential framework that it described as involving a two-axis risk assessment plus a competency assessment. The agency framed that structure as a possible way to categorize and evaluate generative AI-enabled medical devices and asked for feedback on the suitability and implementation of such an approach. The presentation of this possible framework is offered for public input rather than as finalized policy.
How the agency characterized the notice
The FDA reiterated in the Aug. 18 notice that the document is a discussion paper and not a final regulatory rule. The agency explicitly stated the paper does not provide clinical advice. The announcement serves to frame the topics on which the agency seeks stakeholder views and to set a timeline for comment submissions rather than to announce new regulatory requirements.
Docket information and comment timeline
The FDA opened docket number FDA-2026-N-7874 for public comment and set an explicit closing date for submissions. The docket is open until Oct. 19, 2026. Stakeholders and members of the public who wish to submit feedback may use that docket while the comment period is open. The agency indicated that the docket and the discussion paper are part of a process to gather information before any potential regulatory decisions.
Where to find the full announcement
Readers who wish to consult the FDA’s original announcement and the discussion paper can find the agency’s release at the FDA’s website: FDA announcement on generative AI-enabled medical devices. For ongoing coverage of related public health and regulatory developments, see the related reporting category: Health.
The FDA’s action, as described in the announcement, identifies areas where the agency seeks input and presents a potential analytic structure for review. The docket number and comment deadline provide a mechanism and timeline for members of the public and stakeholders to submit observations and perspectives to the agency during the open comment period. Because the document is presented as a discussion paper, the agency is seeking a range of perspectives to inform how it might proceed on regulation of generative AI-enabled medical devices.
What the discussion paper does and does not do
The document is a request for input, not a new binding rule, a product authorization, or an instruction for patients to use a particular technology. FDA says it is seeking feedback from manufacturers, clinicians, consumers, researchers, the public and other interested parties. The agency’s questions cover how potential risks should be assessed before a device reaches patients and how performance could be monitored after deployment.
For readers, the practical date is the comment deadline. The docket remains open through Oct. 19, 2026. People considering a submission can review the paper and the questions FDA posted rather than relying on broad claims about AI in medicine. The agency’s stated aim is to gather evidence for a future regulatory approach that considers both innovation and patient safety.
